Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Sign in
Sign in

Samsung Bioepis teams up with Takeda to develop original biotech drugs

SEOUL (Reuters) - Samsung Bioepis Co Ltd said on Monday it will fund and develop multiple original drugs in partnership with Japan's Takeda Pharmaceutical Co Ltd, expanding its business scope beyond copies of existing biologic drugs.

Original biotech drugs represent a business ramp-up for Samsung Bioepis, which has so far invested $1.3 billion in drug development since being founded in 2012 and has received approvals for two biosimilar drugs in Europe and one in the United States.

Bioepis is part of South Korean conglomerate Samsung Group's biopharmaceutical bet as a future growth engine, along with contract manufacturer parent Samsung BioLogics Co Ltd.

The partnership will develop novel biologic drugs in "unmet disease areas", Bioepis said in a joint statement with Takeda, adding the two companies will immediately begin working on a treatment for severe acute pancreatitis.

They declined to disclose other terms of the development program.

Interest in biosimilars has soared in recent years as copies of some of the world's best-selling biologic medicines have hit the market at big discounts.

As a relative latecomer to the industry, Samsung Bioepis quickly proved its development capabilities by becoming the first firm to launch a biosimilar version of Amgen's blockbuster rheumatoid arthritis drug Enbrel in Europe last year, generating over $250 million in sales so far, according to Bioepis.

It has also received both European and U.S. approval for its copy of Johnson & Johnson's Remicade, and awaits European regulatory decisions for its biosimilar versions of AbbVie Inc's Humira and Roche's Herceptin. [nL3N1KF4OL][nL4N1A40FZ][nL4N1A40FZ]

Samsung Bioepis will also seek partnerships with other drugmakers to become an original drugmaker that can conduct all phases of novel biologics development in 10 years, spokesman Mingi Hyun said.

Samsung Group hopes the biosimilars business will develop into a new growth driver as global demand for smartphones slows, weighing on the outlook for the mobile business of flagship firm Samsung Electronics.

Reporting by Joyce Lee; Editing by Muralikumar Anantharaman

August 21, 2017


0
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote

We use "cookies*  to ensure the functionality of our website, recognise your browser or device, learn more about your interests, and provide you with essential features and services and for additional purposes, including:

Recognising you when you sign-in to use our services. This allows us to provide you with product recommendations, display personalised content, and provide other customised features and services.
Keeping track of your specified preferences. You may set your preferences through Your Account..
Keeping track of items stored in your shopping basket and personal cabinet.
Conducting research and diagnostics to improve ChemDiv’s content, products, and services.
Delivering content, including ads, relevant to your interests on ChemDiv’s site
Reporting. This allows us to measure and analyse the performance of our services.

By  cookies you give consent to the processing of your personal data, including transfer to third parties. Further information can be found in our privacy policy.

Accept all cookies